Overview: Hepatitis B e Antigen TestIntroduction: The Hepatitis B e Antigen Test detects hepatitis B e antigen (HBeAg) to assess active viral replication, causing liver damage. Aligned with 2023 AASLD guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding antiviral therapy, monitoring disease progression, and improving outcomes in serology for patients with chronic hepatitis B, ensuring timely intervention to prevent complications like cirrhosis.
Other Names: HBeAg Assay, Hepatitis B Viral Replication Test.
FDA Status: FDA-cleared diagnostic test, meeting serology standards for diagnostic accuracy.
Historical Milestone: HBeAg testing began in the 1970s with hepatitis B research. Immunoassays improved in the 1980s, enhancing detection of active viral replication.
Purpose: Assesses active hepatitis B viral replication, guides antiviral therapy, and monitors HBeAg in patients with liver pain or fatigue to prevent liver damage.
Test Parameters: 1. Hepatitis B e Antigen
Pretest Condition: No fasting required. Collect serum at any time. Report symptoms like liver pain, fatigue, or jaundice, and list medications, especially antivirals.
Specimen: 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document liver pain, fatigue, jaundice, or history of chronic hepatitis B. Include current medications, antiviral treatment history, and risk factors (e.g., IV drug use).
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy or monitoring.
Procedural Considerations: Uses an immunoassay to detect HBeAg, indicating active viral replication. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often part of hepatitis B monitoring protocols.
Factors Affecting Result Accuracy: Improper sample handling, hemolysis, or antiviral therapy can affect results. Early infection or low viral load may yield false negatives.
Clinical Significance: Positive HBeAg indicates active hepatitis B replication, prompting antiviral therapy. Negative results may suggest low replication or seroconversion, requiring further testing.
Specialist Consultation: Consult a hepatologist for result interpretation and antiviral therapy planning.
Additional Supporting Tests: HBV DNA, anti-HBe, or liver function tests to assess hepatitis B status and liver damage.
Test Limitations: False negatives may occur in low viral load or treated patients. Clinical correlation and serial testing are needed for accurate assessment.
References: AASLD Hepatitis B Guidelines, 2023; Hepatology, Lok AS, 2022.
